

**United States Patent** [19]  
**Mayer et al.**

[11] **Patent Number:** **5,556,838**  
[45] **Date of Patent:** **\*Sep. 17, 1996**

[54] **INHIBITING THE DEVELOPMENT OF  
TOLERANCE TO AND/OR DEPENDENCE ON  
AN ADDICTIVE SUBSTANCE**

[75] **Inventors:** **David J. Mayer; Donald D. Price;  
Jianren Mao, all of Richmond, Va.;  
John W. Lyle, Belmar, N.J.**

[73] **Assignee:** **Virginia Commonwealth University,  
Richmond, Va.**

[\*] **Notice:** The term of this patent shall not extend  
beyond the expiration date of Pat. No.  
5,321,012.

[21] **Appl. No.:** **245,970**

[22] **Filed:** **May 19, 1994**

**Related U.S. Application Data**

[63] **Continuation of Ser. No. 43,280, Apr. 6, 1993, Pat. No.  
5,321,012, which is a continuation-in-part of Ser. No.  
10,583, Jan. 28, 1993, abandoned.**

[51] **Int. Cl.<sup>6</sup>** ..... **A61K 31/70; A61K 31/54;  
A61K 31/44; A61K 31/445**

[52] **U.S. Cl.** ..... **514/25; 514/216; 514/223.5;  
514/225.5; 514/224.5; 514/282; 514/231.2;  
514/304; 514/305; 514/306; 514/307; 514/812**

[58] **Field of Search** ..... **514/25, 304, 305,  
514/306, 307, 216, 223.5, 225.5, 224.5,  
282, 231.2, 812**

[56] **References Cited  
PUBLICATIONS**

Pharmacol. Biochem. Behav. vol. 35, No. 4 (1990), pp.  
829-832.

Pharmacol. Biochem. Behav. vol. 43, No. 2 (1992), pp.  
487-490.

Dtsch. Apoth.-Ztg. vol. 119, No. 21 (1979), p. 821, "Opi-  
at-Rezeptoren und Endorphine".

Truillo et al.; "Inhibition of Morphine . . . MIC801";  
Science; vol. 251, pp. 84-87.

Marek et al; "Brain Research, Delayed application of  
MIC801 . . . in rats."; vol. 558, pp. 163-165.

*Primary Examiner*—Theodore J. Criares  
*Attorney, Agent, or Firm*—Dilworth & Barrese

[57] **ABSTRACT**

Nontoxic substances that block the N-methyl-D-aspartate  
(NMDA) receptor, e.g., a morphinan such as dextrometho-  
rphan or dextrorphan, or that block a major intracellular  
consequence of NMDA-receptor activation, e.g., a ganglio-  
side such as GM<sub>1</sub> or GT<sub>1b</sub>, a phenothiazine such as triflu-  
operazine or a naphthalenesulfonamide such as N-(6-ami-  
nohexyl)-5-chloro-1-naphthalenesulfonamide, inhibit the  
development of tolerance to and/or dependence on addictive  
drugs, e.g., narcotic analgesics such as morphine, codeine,  
etc.

**2 Claims, 10 Drawing Sheets**